TotalMarketCap

CRISPR Therapeutics

CRSPNasdaq SwitzerlandHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$4.712 B

$48.58 -6.17%

Close of 6 Nov 2026

As of 6 Nov 2026, CRISPR Therapeutics (CRSP) has a market capitalization of $4.71B. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$3.51M

#3317 by revenue

Earnings

-$581.6M

Loss-making

Shares outstanding

97,000,813

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →
  1. #21Kodiak SciencesKOD$5.73B
  2. #22Scholar RockSRRK$5.56B
  3. #23CRISPR TherapeuticsCRSP$4.71B
  4. #24Adaptive BiotechnologiesADPT$4.35B
  5. #25Relay TherapeuticsRLAY$3.76B

What if CRISPR Therapeutics were worth as much as…

Open the what-if tool →

Gold $28.2T

$291,099.35

Per share 5,992× higher

Bitcoin $1.53T

$15,750.88

Per share 324× higher

Apple $5.02T

$51,708.67

Per share 1,064× higher

Or at a round number

$10.0B$20.0B$50.0B$100.0B

Where these numbers come from

Share counts and financials for CRISPR Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.